{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=113", "query": { "intervention": "Injectable Placebo", "page": 113 }, "page_size": 10 }, "pagination": { "page": 113, "page_size": 10, "total_count": 4226, "total_pages": 423, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=114&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=112&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T10:36:11.400Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00606489", "title": "Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Burns" ], "interventions": [ { "name": "Caldolor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cumberland Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 61, "start_date": "2007-11", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2011-08-11", "last_synced_at": "2026-11-12T10:36:11.400Z", "location_count": 2, "location_summary": "Orlando, Florida • Winston-Salem, North Carolina", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00606489" }, { "nct_id": "NCT02912468", "title": "A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)" ], "interventions": [ { "name": "Dupilumab SAR231893 (REGN668)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mometasone furoate 50 micrograms", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2016-12-05", "completion_date": "2018-07-05", "has_results": true, "last_update_posted_date": "2019-07-25", "last_synced_at": "2026-11-12T10:36:11.400Z", "location_count": 18, "location_summary": "Long Beach, California • Orange, California • San Diego, California + 15 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Centennial", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02912468" }, { "nct_id": "NCT05492500", "title": "A Study of Ponsegromab in People With Heart Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Main cohort (Cohort A): Ponsegromab low dose", "type": "DRUG" }, { "name": "Main cohort (Cohort A): Ponsegromab medium dose", "type": "DRUG" }, { "name": "Main cohort (Cohort A): ponsegromab high dose", "type": "DRUG" }, { "name": "Main cohort (Cohort A): Matched placebo", "type": "OTHER" }, { "name": "Open-label, PK Cohort (Cohort B): ponsegromab low dose", "type": "DRUG" }, { "name": "Open-label, PK Cohort (Cohort B): ponsegromab medium dose", "type": "DRUG" }, { "name": "Open-label, PK Cohort (Cohort B): ponsegromab high dose", "type": "DRUG" }, { "name": "Optional Cohort C: Ponsegromab low dose", "type": "DRUG" }, { "name": "Optional Cohort C: Matched placebo", "type": "OTHER" }, { "name": "Optional Cohort D: Ponsegromab high dose", "type": "DRUG" }, { "name": "Optional Cohort D: Matched placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 455, "start_date": "2022-09-26", "completion_date": "2025-03-05", "has_results": true, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-11-12T10:36:11.400Z", "location_count": 22, "location_summary": "Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Hazel Crest", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05492500" }, { "nct_id": "NCT01508936", "title": "Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Asthma" ], "interventions": [ { "name": "Reslizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 511, "start_date": "2012-02", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-06-27", "last_synced_at": "2026-11-12T10:36:11.400Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01508936" }, { "nct_id": "NCT02193087", "title": "Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dengue Fever" ], "interventions": [ { "name": "TDV Liquid Formulation 1", "type": "DRUG" }, { "name": "TDV Liquid Formulation 2", "type": "DRUG" }, { "name": "TDV IDT Lyophilized", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 1002, "start_date": "2014-08-06", "completion_date": "2015-05-19", "has_results": true, "last_update_posted_date": "2019-07-18", "last_synced_at": "2026-11-12T10:36:11.400Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Anaheim, California • Stockbridge, Georgia + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Stockbridge", "state": "Georgia" }, { "city": "Meridian", "state": "Idaho" }, { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02193087" }, { "nct_id": "NCT02016716", "title": "A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Postmenopausal Osteoporosis" ], "interventions": [ { "name": "Romosozumab 90 mg/mL", "type": "DRUG" }, { "name": "Placebo 90 mg/mL", "type": "DRUG" }, { "name": "Romosozumab 70 mg/mL", "type": "DRUG" }, { "name": "Placebo 70 mg/mL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "55 Years to 90 Years · Female only" }, "enrollment_count": 294, "start_date": "2013-12-03", "completion_date": "2014-12-08", "has_results": true, "last_update_posted_date": "2018-11-08", "last_synced_at": "2026-11-12T10:36:11.400Z", "location_count": 2, "location_summary": "Gainesville, Georgia • Bethesda, Maryland", "locations": [ { "city": "Gainesville", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02016716" }, { "nct_id": "NCT04513652", "title": "A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anesthesia, Local" ], "interventions": [ { "name": "AG-920", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Genomics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2020-09-03", "completion_date": "2020-12-17", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-11-12T10:36:11.400Z", "location_count": 1, "location_summary": "Newport Beach, California", "locations": [ { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04513652" }, { "nct_id": "NCT04474847", "title": "Abatacept for the Treatment of Giant Cell Arteritis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Giant Cell Arteritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 78, "start_date": "2021-03-29", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-12T10:36:11.400Z", "location_count": 5, "location_summary": "Rochester, Minnesota • New York, New York • Cleveland, Ohio + 2 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04474847" }, { "nct_id": "NCT04368728", "title": "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "SARS-CoV-2 Infection", "COVID-19" ], "interventions": [ { "name": "BNT162b1", "type": "BIOLOGICAL" }, { "name": "BNT162b2", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "BNT162b2SA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 46969, "start_date": "2020-04-29", "completion_date": "2023-02-10", "has_results": true, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-11-12T10:36:11.400Z", "location_count": 154, "location_summary": "Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04368728" }, { "nct_id": "NCT04865211", "title": "Does a ThoracoLumbar Interfacial Plane (TLIP) Block With Liposomal Bupivacaine Provide TLIP Block in Spinal Surgery", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pain, Postoperative" ], "interventions": [ { "name": "Liposomal bupivacaine", "type": "DRUG" }, { "name": "Bupivacaine Injection", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cooper Norcross Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2021-04-05", "completion_date": "2022-04-30", "has_results": false, "last_update_posted_date": "2021-04-29", "last_synced_at": "2026-11-12T10:36:11.400Z", "location_count": 1, "location_summary": "Camden, New Jersey", "locations": [ { "city": "Camden", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04865211" } ] }